Trials / Completed
CompletedNCT04329975
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet 25μg / 50μg in Treatment for Male Nocturia Due to Nocturnal Polyuria
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,087 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the incidence and risk factors of desmopressin-induced hyponatremia during long-term treatment (1 year \[52 weeks\]) of MINIRINMELT orally disintegrating (OD) tablets 25μg/50μg (drug) for nocturia caused by nocturnal polyuria in men in daily clinical practice, and to confirm the compliance with proper use of this drug in clinical practice and to investigate the effectiveness of risk minimization activities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desmopressin | Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally. |
Timeline
- Start date
- 2020-05-19
- Primary completion
- 2024-09-25
- Completion
- 2024-09-25
- First posted
- 2020-04-01
- Last updated
- 2024-12-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04329975. Inclusion in this directory is not an endorsement.